Myeloid leukemia-1 expression in benign and malignant melanocytic lesions

Oncol Rep. 2008 Apr;19(4):933-7.

Abstract

Myeloid leukemia-1 (Mcl-1) is an anti-apoptotic protein implicated in tumor progression. Its expression was found to be elevated in many types of human cancers and is correlated with tumor progression. The expression of Mcl-1 in melanoma is not fully understood. We investigated the expression of Mcl-1 in normal nevi, dysplastic nevi, primary melanoma and melanoma metastases by tissue microarray and immunohistochemistry. We found that Mcl-1 expression was significantly increased in dysplastic nevi, primary melanoma and melanoma metastases when compared to normal nevi, though the expression of Mcl-1 was decreased in metastatic melanoma when compared to dysplastic nevi. We did not find any correlation between Mcl-1 expression and melanoma patient survival. Our data suggest that Mcl-1 may play a critical role in the initiation of melanoma development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Apoptosis
  • Dysplastic Nevus Syndrome / metabolism*
  • Dysplastic Nevus Syndrome / mortality
  • Dysplastic Nevus Syndrome / pathology
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Melanoma / chemistry*
  • Melanoma / mortality
  • Melanoma / pathology
  • Melanoma / secondary
  • Middle Aged
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Neoplasm Proteins / analysis*
  • Nevus / chemistry*
  • Nevus / mortality
  • Nevus / pathology
  • Proto-Oncogene Proteins c-bcl-2 / analysis*
  • Tissue Array Analysis

Substances

  • Myeloid Cell Leukemia Sequence 1 Protein
  • Neoplasm Proteins
  • Proto-Oncogene Proteins c-bcl-2